| With the decrease ROI in R & D spending, pharmaceutical companies are trying to grab the market share with Licensing or M&A as much as they can. On the one hand, they become cautious and discerning in transactions; on the other hand, they spend a lot of money on high-quality assets. The market has more uncertainty in 2020 due to the impact of coronavirus. Still, it does not seem to prevent the life science people from moving forward, either to begin clinical trial rapidly or to speed up a large number of mergers and acquisitions. Ms. Tina Zhao, from Clarivate, will review the major deals with you in the pharmaceutical field in the past year and will review and comment on the deals of the Chinese market. We believe the 2019 Deals Review and Deals in China will support your business decisions in the future. |
No comments:
Post a Comment